Karus Therapeutics
Karus Therapeutics is a privately held, UK-based pharmaceutical company founded in 2005 that designs and develops molecular-targeted small-molecule drugs to treat cancer, operating as an early-stage oncology drug discovery entity with no commercial product yet disclosed.
- Company typePrivate
- Founded2005
- HeadquartersChilworth, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Karus Therapeutics firmographics
Firmographics- Name
- Karus Therapeutics
- Website
- https://karustherapeutics.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Karus Therapeutics is a privately held, UK-based pharmaceutical company founded in 2005 that designs and develops molecular-targeted small-molecule drugs to treat cancer, operating as an early-stage oncology drug discovery entity with no commercial product yet disclosed.
- Ownership category
- akta.pro rank
Karus Therapeutics industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
Keywords
Where Karus Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Chilworth
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Karus Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Karus Therapeutics product offering
Product offeringCore offering
Karus Therapeutics is a pharmaceutical company focused on the design and development of molecular-targeted, small molecule drugs to treat cancer. Its work centers on discovering and advancing small-molecule oncology candidates from research through development.
Differentiator
Problem solved
Functional benefit
Products and services
- Molecular-targeted small-molecule oncology drug candidates A pipeline of small-molecule, molecularly targeted drug candidates designed to treat cancer. Intended for eventual out-licensing, partnership, or acquisition by larger pharmaceutical companies to advance into clinical development.
Companies that use Karus Therapeutics
Customer profileIdeal customer profiles1 record
Karus Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Karus Therapeutics competitors and assessment
Company assessmentDirect peers
- Vernalis (now HitGen): Originally a UK-based small molecule structure-based drug discovery company focused on oncology and CNS; highly comparable given shared UK roots, SBDD heritage, and oncology focus.
- Redx Pharma: UK-based small molecule drug discovery and development company with oncology and fibrosis programs; direct comparable in geography, modality, and small-cap biotech structure.
- NuCana: Clinical-stage oncology company developing small molecule nucleotide analogues (ProTide technology); directly comparable as a small-cap targeted oncology developer.
- Aprea Therapeutics: Clinical-stage small molecule oncology company developing targeted therapies (e.g., PRIMA-1MET for p53 reactivation); direct functional analogue as a small-cap, target-focused cancer drug developer.
- Bicycle Therapeutics: UK-based targeted therapeutics company with oncology pipeline built around a proprietary small molecule–like scaffold; comparable UK small-cap oncology developer.
- Cyclacel Pharmaceuticals: Clinical-stage small molecule oncology company developing CDK inhibitors and related targeted drugs; directly comparable in modality, stage profile, and small-cap funding scale.
- Syros Pharmaceuticals: Small molecule oncology company focused on cell-cycle and transcriptional regulation; comparable development-stage peer in targeted cancer drug discovery with similar capital profile.
- Sareum Holdings: UK-based small molecule drug discovery company focused on cancer and autoimmune disease; strong direct peer given shared geography, modality (small molecules), and development-stage status.
Emerging players
- Selvita: Europe-based small molecule discovery and development CRO/emerging sponsor with oncology portfolio; comparable as a smaller-scale small molecule oncology developer with services business underpinning.
Broad incumbents
- Astex Pharmaceuticals: UK-based structure-based small molecule drug discovery company with broad oncology programs, acquired by Otsuka; broader incumbent peer in the same UK small-molecule oncology niche.
Market position
Customer concentration
Karus Therapeutics social profiles
Digital presenceKarus Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Karus Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Karus Therapeutics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Karus Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Karus Therapeutics
What does Karus Therapeutics do?
Karus Therapeutics is a pharmaceutical company focused on the design and development of molecular-targeted, small molecule drugs to treat cancer. Its work centers on discovering and advancing small-molecule oncology candidates from research through development.
When was Karus Therapeutics founded?
Karus Therapeutics was founded in 2005. It employs 11 to 50 people.
Where is Karus Therapeutics based?
Karus Therapeutics is headquartered in Chilworth, United Kingdom, in the Europe region.
Who are Karus Therapeutics's main competitors?
Direct peers on record are Vernalis (now HitGen), Redx Pharma, NuCana, Aprea Therapeutics, Bicycle Therapeutics, Cyclacel Pharmaceuticals, Syros Pharmaceuticals and Sareum Holdings. Selvita is listed as an emerging player. Astex Pharmaceuticals is listed as a broad incumbent.
Does Karus Therapeutics have an API?
No public API is recorded for Karus Therapeutics.
What industry is Karus Therapeutics in?
Karus Therapeutics's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology. Its NAICS code is 541714 and its SIC code is 2834.